title: The association of rs1051730 genotype on adherence to and consumption of prescribed nicotine replacement therapy dose during a smoking cessation attempt.
abstract: BACKGROUND
  While nicotine replacement therapy (NRT) is an effective pharmacological smoking cessation treatment, its efficacy is influenced by adherence to and consumption of the prescribed dose. The genetic variant rs1051730 in the nicotinic receptor gene cluster CHRNA5-A3-B4 influences smoking quantity. The aim of this study was to explore the impact of rs1051730 genotype on adherence to and consumption of NRT prescription following a smoking cessation attempt.
  
  
  METHODS
  Secondary analysis of data from a pharmacogenetic smoking cessation trial. Participants (n = 448) were prescribed a daily dose of NRT for four weeks post quit attempt, and monitored during weekly clinic visits. Outcome measures were NRT prescription adherence rate (%) and average daily NRT consumption (mg) at 7- and 28-days after the quit attempt.
  
  
  RESULTS
  An association between rs1051730 genotype and both outcome measures was observed at 7-days after the quit date. Each copy of the minor allele corresponded to a 2.9% decrease in adherence to prescribed NRT dose (P = 0.044), and a 1.0mg decrease in daily NRT consumption (P = 0.026). Adjusting for number of cigarettes smoked during this period only slightly attenuated these associations. There was no clear statistical evidence of an association between genotype and adherence or consumption at 28-days.
  
  
  CONCLUSIONS
  This is the first study to evaluate the impact of rs1051730 genotype on consumption of and adherence to NRT prescription during a smoking cessation attempt. We observed an association between this variant and both outcome measures at 7-days; however, this was only moderate. These findings require replication in an independent sample.
authors.affiliation: MRC Integrative Epidemiology Unit (IEU) at the University of Bristol, BS8 2BN Bristol, United Kingdom; School of Social and Community Medicine, Oakfield House, Oakfield Grove, Bristol BS8 2BN, United Kingdom. Electronic address: jen.ware@bristol.ac.uk.
authors.forename: Jennifer J
authors.initials: JJ
authors.lastname: Ware
authors.affiliation: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, United Kingdom.
authors.forename: Paul
authors.initials: P
authors.lastname: Aveyard
authors.affiliation: Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom.
authors.forename: Peter
authors.initials: P
authors.lastname: Broderick
authors.affiliation: Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom.
authors.forename: Richard S
authors.initials: RS
authors.lastname: Houlston
authors.affiliation: Cambridge University Health Partners, Addenbrookes Hospital, Cambridge CB2 0QQ, United Kingdom.
authors.forename: Timothy
authors.initials: T
authors.lastname: Eisen
authors.affiliation: MRC Integrative Epidemiology Unit (IEU) at the University of Bristol, BS8 2BN Bristol, United Kingdom; UK Centre for Tobacco and Alcohol Studies and School of Experimental Psychology, University of Bristol, 12a Priory Road, Bristol BS8 1TU, United Kingdom.
authors.forename: Marcus R
authors.initials: MR
authors.lastname: Munafò
mesh_terms: D000483:Alleles; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009538:Nicotine / Q000627:therapeutic use*; D018722:Nicotinic Agonists / Q000627:therapeutic use*; D011978:Receptors, Nicotinic / Q000235:genetics*; D016540:Smoking Cessation / Q000523:psychology*; D012959:Socioeconomic Factors; D016896:Treatment Outcome
chemical_list: D018722:Nicotinic Agonists; D011978:Receptors, Nicotinic; D009538:Nicotine
keywords: Cessation; Genetics; Nicotine replacement therapy; Smoking